GSK, Cure­Vac forge ahead with mid-stage plans for flu, Covid mR­NA vac­cines

GSK-part­nered mR­NA biotech Cure­Vac re­leased in­ter­im Phase I da­ta on its new mR­NA vac­cines for Covid and the flu, caus­ing its stock $CVAC to jump 25%.

While the da­ta are ear­ly and main­ly ad­dress the safe­ty of the new vac­cines, Cure­Vac CEO Franz-Wern­er Haas told End­points News that re­leas­ing the in­ter­im da­ta was the biotech’s way of say­ing, “Yes, we are back in the race.”

Cure­Vac’s first at­tempt at an mR­NA vac­cine flamed out af­ter it failed its piv­otal tri­al, which Cure­Vac at­trib­uted in part to the rise of new vari­ants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER